Ovarian Cancer Clinical Trials in Birmingham, Alabama

12 studies are recruiting for ovarian cancer in Birmingham, Alabama right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

   Researchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as much of the cancer as possible. After surgery, people may receive chemotherapy. After chemotherapy, standard care options may include: * Maintenance treatment, which is us…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   University of Alabama - Birmingham ( Site 0058), Birmingham, Alabama

   Locations

   163 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT07318558 on ClinicalTrials.gov

2. FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

   The purpose of this multicenter, open label trial (NAPISTAR 1-01) is to evaluate the safety/tolerability, pharmacokinetics and preliminary efficacy of TUB-040 and to find the best dose of TUB-040 in participants with ovarian cancer and Non Small Cell Lung Cancer. TUB-040 is an antibody-drug-conjuga…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The University of Alabama, Birmingham, Alabama

   Locations

   29 in total

   Run by

   Tubulis GmbH

   See if you can join NCT06303505 on ClinicalTrials.gov

3. Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

   This study is researching an experimental drug called ubamatamab, also referred to as "study drug". The study is focused on participants who have advanced ovarian cancer. The aim of the study is to see how safe, tolerable, and effective the study drug is on its own and in combination with other ant…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   The University of Alabama at Birmingham, Birmingham, Alabama

   Locations

   56 in total

   Run by

   Regeneron Pharmaceuticals

   See if you can join NCT06787612 on ClinicalTrials.gov

4. Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

   The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Alabama Birmingham, Birmingham, Alabama

   Locations

   26 in total

   Run by

   SystImmune Inc.

   See if you can join NCT06293898 on ClinicalTrials.gov

5. A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

   The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and if people who take sacituzumab tirumotecan with or without bevacizumab live longer without the cancer getting worse than those who receive standard of care treatment.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   University of Alabama at Birmingham ( Site 0006), Birmingham, Alabama

   Locations

   196 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06824467 on ClinicalTrials.gov

6. DESTINY-PANTUMOUR04

   This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options in a real-world…

   Stage

   Not phased

   Ages

   18 to 130

   Site

   Research Site, Birmingham, Alabama

   Locations

   18 in total

   Run by

   AstraZeneca

   See if you can join NCT07124000 on ClinicalTrials.gov

7. A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

   This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone and in combination with gemcitabine or irinotecan * Learn more…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Alabama at Birmingham, Birmingham, Alabama

   Locations

   82 in total

   Run by

   Artios Pharma Ltd

   See if you can join NCT04657068 on ClinicalTrials.gov

8. The DETECT Study: Discovery and Evaluation of Testing for Endometrial and Ovarian Cancer in Tampons

   BACKGROUND: Endometrial cancer is a common and deadly cancer for women. It is getting more common and deadly because risk factors like age and obesity are increasing. Also, this cancer is becoming more common and deadly for black women than white women. Researchers want to find better ways to take …

   Stage

   Not phased

   Ages

   18 to 99

   Site

   University of Alabama at Birmingham, Birmingham, Alabama

   Run by

   University of Alabama at Birmingham

   See if you can join NCT03538665 on ClinicalTrials.gov

9. Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

   This is a Phase 2, open-label, global, multi-arm study to evaluate efficacy and safety of relacorilant in combination with other treatments in patients with gynecological cancers.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   004, Birmingham, Alabama

   Locations

   49 in total

   Run by

   Corcept Therapeutics

   See if you can join NCT06906341 on ClinicalTrials.gov

10. Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer

    The proposed study design is a single arm Phase II trial to document the feasibility of carboplatin-mirvetuximab - in patients with advanced-stage EOC. Patients with biopsy confirmed, newly diagnosed, advanced-stage serous EOC deemed appropriate for NACT will have their tumors evaluated for FRα rec…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of Alabama at Birmingham Womens & Infants Center, Birmingham, Alabama

    Locations

    9 in total

    Run by

    University of Alabama at Birmingham

    See if you can join NCT04606914 on ClinicalTrials.gov

11. Newly Diagnosed Stage III/IV Ovarian Cancer, Neoadjuvant Carbo/Taxol/Pembro, Maintenance Olaparib/Pembro

    this is a trial evaluating three chemotherapy agents in patients with newly diagnosed ovarian cancer patients that are Stage III or Stage IV prior to surgery to remove the tumor. After surgery there will be additional chemotherapy given.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    O'Neal Comprehensive Cancer Center at UAB, Birmingham, Alabama

    Run by

    University of Alabama at Birmingham

    See if you can join NCT05952453 on ClinicalTrials.gov

12. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

    International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

    Stage

    Not phased

    Ages

    Any age

    Site

    Massive Bio SYNERGY-AI site, Birmingham, Alabama

    Locations

    68 in total

    Run by

    Massive Bio, Inc.

    See if you can join NCT03452774 on ClinicalTrials.gov